RT Journal Article
SR Electronic
T1 Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.03.21251066
DO 10.1101/2021.03.03.21251066
A1 Müller, Lisa
A1 Andrée, Marcel
A1 Moskorz, Wiebke
A1 Drexler, Ingo
A1 Walotka, Lara
A1 Grothmann, Ramona
A1 Ptok, Johannes
A1 Hillebrandt, Jonas
A1 Ritchie, Anastasia
A1 Rabl, Denise
A1 Ostermann, Philipp Niklas
A1 Robitzsch, Rebekka
A1 Hauka, Sandra
A1 Walker, Andreas
A1 Menne, Christopher
A1 Grutza, Ralf
A1 Timm, Jörg
A1 Adams, Ortwin
A1 Schaal, Heiner
YR 2021
UL http://medrxiv.org/content/early/2021/03/05/2021.03.03.21251066.abstract
AB Background The SARS-CoV-2 pandemic has led to the development of various vaccines. Real-life data on immune responses elicited in the most vulnerable group of vaccinees over 80 years old is still underrepresented despite the prioritization of the elderly in vaccination campaigns.Methods We conducted a cohort study with two age groups, young vaccinees below the age of 60 and elderly vaccinees over the age of 80, to compare their antibody responses to the first and second dose of the BNT162b2 COVID-19 vaccination.Results While the majority of participants in both groups produced specific IgG antibody titers against SARS-CoV-2 spike protein, titers were significantly lower in elderly participants. Although the increment of antibody levels after the second immunization was higher in elderly participants, the absolute mean titer of this group remained lower than the <60 group. After the second vaccination, 31.3 % of the elderly had no detectable neutralizing antibodies in contrast to the younger group, in which only 2.2% had no detectable neutralizing antibodies.Conclusion Our data suggests that lower frequencies of neutralizing antibodies after BNT162b2 vaccination in the elderly population may require earlier revaccination to ensure strong immunity and protection against infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Stiftung für Altersforschung, Düsseldorf for [to H.S., L.W.], Jürgen Manchot foundation [to H.S., I.D. L.M., L.W., A.R., J.T., R.G., P.N.O.]. This work was supported by research funding from Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) grant GK1949/1 and project number 452147069 [to I.D.]. This work was supported by the Forschungskommission of the Medical Faculty, Heinrich-Heine-Universität Düsseldorf [to H.S., J.P., J.H.]Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the Medical Faculty at the Heinrich-Heine University Düsseldorf, Germany (study no. 2021-1287), approved the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThere is no supplemental data available.